Scpharmaceuticals Inc (SCPH) - Total Assets
Based on the latest financial reports, Scpharmaceuticals Inc (SCPH) holds total assets worth $80.25 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Scpharmaceuticals Inc (SCPH) shareholders funds for net asset value and shareholders' equity analysis.
Scpharmaceuticals Inc - Total Assets Trend (2015–2024)
This chart illustrates how Scpharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Scpharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Scpharmaceuticals Inc's total assets of $80.25 Million consist of 98.5% current assets and 1.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.4% |
| Accounts Receivable | $11.72 Million | 10.9% |
| Inventory | $13.90 Million | 12.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Scpharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SCPH company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scpharmaceuticals Inc's current assets represent 98.5% of total assets in 2024, a decrease from 98.5% in 2015.
- Cash Position: Cash and equivalents constituted 70.4% of total assets in 2024, down from 85.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 12.9% of total assets.
Scpharmaceuticals Inc Competitors by Total Assets
Key competitors of Scpharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Scpharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.85 | 4.84 | 16.07 |
| Quick Ratio | 3.14 | 3.66 | 15.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $58.30 Million | $49.70 Million | $108.49 Million |
Scpharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Scpharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.45 |
| Latest Market Cap to Assets Ratio | 2.83 |
| Asset Growth Rate (YoY) | 13.8% |
| Total Assets | $107.52 Million |
| Market Capitalization | $304.36 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Scpharmaceuticals Inc's assets at a significant premium (2.83x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Scpharmaceuticals Inc's assets grew by 13.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Scpharmaceuticals Inc (2015–2024)
The table below shows the annual total assets of Scpharmaceuticals Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $107.52 Million | +13.80% |
| 2023-12-31 | $94.48 Million | -23.93% |
| 2022-12-31 | $124.19 Million | +57.14% |
| 2021-12-31 | $79.04 Million | -27.52% |
| 2020-12-31 | $109.05 Million | +41.10% |
| 2019-12-31 | $77.28 Million | -17.57% |
| 2018-12-31 | $93.75 Million | -23.18% |
| 2017-12-31 | $122.05 Million | +206.87% |
| 2016-12-31 | $39.77 Million | +2054.50% |
| 2015-12-31 | $1.85 Million | -- |
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more